Rescue Progesterone Supplementation During Frozen Embryo Transfer
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Endometrin is a progesterone supplement prescribed during in vitro fertilization (IVF) for
preparation for embryo transfer. The usual dose of Endometrin is 100 mg two to three times
per day in the form of an effervescent tablet to be inserted vaginally.
The purpose of this research project is to evaluate the dose response of the Endometrin when
determined based on the blood level of progesterone on the day of the FET. According to the
literature, a predefined level of progesterone in the blood should be reached in order to
have favorable conditions for pregnancy. The hypothesis being that a woman with low
progesterone levels would benefit from a dose of Endometrin of 600 mg (200 mg 3x/day) to
decrease the risk of miscarriage and improve the chances of pregnancy. Women with adequate
progesterone levels according to the literature, would continue with the standard dose of
progesterone prescribed at clinique ovo which is 300 mg (100 mg 3x/day).
PIBF (Progesterone Induced Blocking Factor) levels, a protein found in the blood that could
also predict pregnancy outcomes in women using IVF will also be looked at.